Over the years, targeting malfunctioning PI3K/AKT/mTOR has been considered an attractive therapeutic target, especially in the MBC metastatic setting, as activation of this signalling axis has been linked to cancer progression and metastasization [10, 42]. The gene discussed is PIK3CA; the disease is cancer.